STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[SCHEDULE 13G/A] CervoMed Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

CervoMed Inc. Schedule 13G/A filed by RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., Peter Kolchinsky and Rajeev Shah reports that each Reporting Person holds zero shares of CervoMed common stock representing 0.0% of the class as shown on the cover pages. The filers state they are not acting as a group and that the securities were not acquired to influence control of the issuer. The principal business address for the Reporting Persons is c/o RA Capital Management, L.P., Boston, MA.

Positive
  • None.
Negative
  • None.

Insights

TL;DR Report shows no beneficial ownership by the listed RA Capital parties, indicating no current economic stake.

The filing is a routine Schedule 13G/A amendment that documents 0 shares (0.0%) beneficially owned by each Reporting Person. For investors, this filing signals that these entities and individuals do not hold a disclosed equity position in CervoMed and thus exert no reported voting or dispositive influence through ownership. The statement's certification that holdings were not acquired to influence control reinforces a non-activist posture.

TL;DR Governance impact is neutral: the filers disclaim group status and report no ownership, so no change to control dynamics.

From a governance standpoint, the disclosure clarifies that RA Capital and associated individuals do not constitute a shareholder block and have not accumulated shares that would affect board influence or control. The included certification aligns with passive reporting standards. The joint filing agreement is referenced, indicating coordinated reporting mechanics but not coordinated ownership or activism.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



RA Capital Management, L.P.
Signature:/s/ Peter Kolchinsky
Name/Title:By Peter Kolchinsky, Authorized Signatory
Date:08/14/2025
Peter Kolchinsky
Signature:/s/ Peter Kolchinsky
Name/Title:Peter Kolchinsky
Date:08/14/2025
Rajeev Shah
Signature:/s/ Rajeev Shah
Name/Title:Rajeev Shah
Date:08/14/2025
RA Capital Healthcare Fund, L.P.
Signature:/s/ Peter Kolchinsky
Name/Title:By RA Capital Healthcare Fund GP, LLC, its General Partner, By Peter Kolchinsky, Manager
Date:08/14/2025
Exhibit Information

Exhibit 99.1 Joint Filing Agreement (incorporated by reference to Exhibit 99.1 to Schedule 13G/A filed on February 14, 2025)

CervoMed

NASDAQ:CRVO

CRVO Rankings

CRVO Latest News

CRVO Latest SEC Filings

CRVO Stock Data

83.37M
6.28M
31.4%
23.56%
3.24%
Biotechnology
Pharmaceutical Preparations
Link
United States
BOSTON